[1]RUDD K E, JOHNSON S C, AGESA K M, et al.Global,regional,and national sepsis incidence and mortality,1990-2017: analysis for the Global Burden of Disease Study[J].Lancet, 2020, 395(10219):200-11
[2]MA S, EVANS R G, IGUCHI N, et al.Sepsis-induced acute kidney injury: A disease of the microcirculation[J].Microcirculation, 2019, 26(2):e12483-
[3]KAUVAR D S, LEFERING R, WADE C E.Impact of hemorrhage on trauma outcome: an overview of epidemiology,clinical presentations,and therapeutic considerations[J].J Trauma, 2006, 60(6 Suppl):S3-11
[4]KUSHIMOTO S, AKAISHI S, SATO T, et al.Lactate,a useful marker for disease mortality and severity but an unreliable marker of tissue hypoxiahypoperfusion in critically ill patients[J].Acute Med Surg, 2016, 3(4):293-7
[5]RISHU A H, KHAN R, AL-DORZI H M, et al.Even mild hyperlactatemia is associated with increased mortality in critically ill patients[J].Crit Care, 2013, 17(5):R197-
[6]KHOSRAVANI H, SHAHPORI R, STELFOX H T, et al.Occurrence and adverse effect on outcome of hyperlactatemia in the critically ill[J].Crit Care, 2009, 13(3):R90-
[7]REWA O G, VILLENEUVE P M, LACHANCE P, et al.Quality indicators of continuous renal replacement therapy (CRRT) care in critically ill patients: a systematic review[J].Intensive Care Med, 2017, 43(6):750-63
[8]KOBAYASHI S, GANDO S, MORIMOTO Y, et al.Serial measurement of arterial lactate concentrations as a prognostic indicator in relation to the incidence of disseminated intravascular coagulation in patients with systemic inflammatory response syndrome[J].Surg Today, 2001, 31(10):853-9
[9]UCHINO S, BELLOMO R, MORIMATSU H, et al.Continuous renal replacement therapy: a worldwide practice surveyThe beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators[J].Intensive Care Med, 2007, 33(9):1563-70
[10]KHWAJA A.KDIGO clinical practice guidelines for acute kidney injury[J].Nephron Clin Pract, 2012, 120(4):c179-84
[11]LI P, ZHANG L, LIN L, et al.Effect of Dynamic Circuit Pressures Monitoring on the Lifespan of Extracorporeal Circuit and the Efficiency of Solute Removal During Continuous Renal Replacement Therapy [J]. Front Med (Lausanne), 2021, 8: 621921.[J].Front Med (Lausanne), 2021, 8( 621921):-
[12]GATTAS D J, RAJBHANDARI D, BRADFORD C, et al.A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults[J].Crit Care Med, 2015, 43(8):1622-9
[13]BAI M, YU Y, ZHAO L, et al.Regional Citrate Anticoagulation versus No Anticoagulation for CKRT in Patients with Liver Failure with Increased Bleeding Risk[J].Clin J Am Soc Nephrol, 2024, 19(2):151-60
[14]朱倩莹, 程立新, 黄兰.甲磺酸萘莫司他体外抗凝在脓毒症合并急性肾损伤患者连续性肾脏替代治疗中的应用评价[J].华西医学, 2023, 38(05):718-23
[15]LI L, BAI M, YU Y, et al.Regional citrate anticoagulation vs no-anticoagulation for CRRT in hyperlactatemia patients with increased bleeding risk: A retrospective cohort study [J]. Semin Dial, 2020.[J].Semin Dial, 2020, :-
[16]LEGRAND M, TOLWANI A.Anticoagulation strategies in continuous renal replacement therapy[J].Semin Dial, 2021, 34(6):416-22
[17]ASSEFI M, LEURENT A, BLANCHARD F, et al.Impact of increasing post-filter ionized calcium target on filter lifespan in renal replacement therapy with regional citrate anticoagulation: A before-and-after study [J]. J Crit Care, 2023, 78: 154364.[J].J Crit Care, 2023, 78(154364):-
[18]MARIANO F, TEDESCHI L, MORSELLI M, et al.Normal citratemia and metabolic tolerance of citrate anticoagulation for hemodiafiltration in severe septic shock burn patients[J].Intensive Care Med, 2010, 36(10):1735-43
[19]MARTEL N, LEE J, WELLS P S.Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis[J].Blood, 2005, 106(8):2710-5
[20]LIU S Y, XU S Y, YIN L, et al.Management of regional citrate anticoagulation for continuous renal replacement therapy: guideline recommendations from Chinese emergency medical doctor consensus[J].Mil Med Res, 2023, 10(1):23-
[21]杨晓波, 王金柱, 刘明晨.枸橼酸钠在脓毒症伴高危出血因素患者行连续性肾脏替代治疗中的应用效果分析[J].护理与康复, 2018, 17(09):10-4
[22]YUE Q, WU H, XI M, et al.Filter Lifespan,Treatment Effect,and Influencing Factors of Continuous Renal Replacement Therapy for Severe Burn Patients[J].J Burn Care Res, 2024, 45(3):764-70
[23]GAO J, WANG F, WANG Y, et al.A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding[J].Sci Rep, 2019, 9(1):6607-
[24]TO H H M, KWAN A M C, LEUNG N Y Y, et al.A prospective study on serum citrate levels and clinical correlations in patients receiving regional citrate anticoagulation[J].Clin Kidney J, 2023, 16(2):285-92
[25]BIANCHI N A, ALTARELLI M, ECKERT P, et al.Complications of Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy: An Observational Study[J].Blood Purif, 2020, 49(5):567-75
[26]郑燚, 孙献坤, 王芳.伴高乳酸血症连续性肾替代治疗患者应用局部枸橼酸抗凝的研究进展[J].中华肾脏病杂志, 2024, 40(04):325-9
[27]KHADZHYNOV D, DAHLINGER A, SCHELTER C, et al.Hyperlactatemia,Lactate Kinetics and Prediction of Citrate Accumulation in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation[J].Crit Care Med, 2017, 45(9):e941-e6
[28]LANG Y, ZHENG Y, QI B, et al.Anticoagulation with nafamostat mesilate during extracorporeal life support [J]. Int J Cardiol, 2022, 366: 71-9.[J].Int J Cardiol, 2022, (366):71-9
[29]CHOI J Y, KANG Y J, JANG H M, et al.Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial[J].Medicine (Baltimore), 2015, 94(52):e2392-
[30]周炜, 陶芸, 韩林.甲磺酸萘莫司他抗凝在心血管外科术后高危出血风险患者连续性肾脏替代治疗中应用[J].世界临床药物, 2022, 43(09):1143-7
[31]KAMIJO H, MOCHIZUKI K, NAKAMURA Y, et al.Nafamostat Mesylate Improved Survival Outcomes of Sepsis Patients Who Underwent Blood Purification: A Nationwide Registry Study in Japan [J]. J Clin Med, 2020, 9(8).[J].J Clin Med, 2020, 9(8):-
[32]赵敏敏, 李长秀, 高菲.萘莫司他与枸橼酸钠抗凝在脓毒症患者连续性肾脏替代治疗中的应用分析[J].中国处方药, 2024, 22(09):122-7
[33]DOI K, IKEDA M, HAYASE N, et al.Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series[J].Crit Care, 2020, 24(1):392-
[34]DUEWELL B E, BRISKI M J, FEIH J T, et al.Argatroban Versus Bivalirudin in the Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia[J].J Pharm Pract, 2021, 34(4):529-34
[35]FERGUSON L M, DREISBACH A W, CSONGRADI E, et al.Recurring extracorporeal circuit clotting during continuous renal replacement therapy in fungal sepsis: successful treatment with argatroban[J].Am J Med Sci, 2013, 345(3):256-8
[36]盛晓华, 李军辉, 范瑛.阿加曲班抗凝法在伴有血小板减少的脓毒血症患者行连续性肾脏替代治疗中的应用[J].中华临床医师杂志电子版, 2015, 9(23):4272-6
